foxo4-dri human trial senolytic Development of a novel by precise disruption of FOXO4-p53 complex FOXO4-DRI - Averix Labs

Common (5-15% of users): Mild injection site reactions, minor digestive changes Uncommon (1-5%): Sleep changes, temporary fatigue, mild headache Rare (under 1%): Dizziness, flushing, mood changes Very Rare: Serious adverse effects rarely reported in community use Theoretical Concerns BPC-157s ability to stimulate angiogenesis (blood vessel formation) raises theoretical questions about its use in individuals with active cancer or high cancer risk

4) Cost transparency & patient trust Pricing for compounded medications is notoriously opaque and varies widely by pharmacy

2001

PubMed Kruse, T., Wendelboe, P., Kragelund, R.P., Pettersson, I., Kaae, S., Hansen, J.B., et al

Even with weekly injections for a full year, the cumulative weekly B6 dose from the compound alone ranges from 5 to 10 mg, far below the levels associated with neuropathy